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The number of cell and gene therapy products approved in North America now exceeds 15, creating a need for 
bioprocesses tailored to this type of biologics. The Stem Cell Bioprocessing Laboratory at McGill, led by Dr. 
Hoesli, Canada Research Chair in Cellular Therapy Bioprocess Engineering, is developing new materials and 
methods to produce and deliver promising cell-based products – in particular for the treatment of diabetes and 
cardiovascular disease. Type 1 diabetes is an autoimmune disease leading to the loss of the insulin-producing 
beta cells of the pancreas. Islet transplantation aims to replace these insulin producing cells rather than 
replacing the missing insulin hormone. Over 85% of islet transplant recipients can live without insulin injections 
for at least 1 year [1], with some patients remaining insulin-independent for over 5 years. Access to this 
promising long-term treatment to diabetes is limited by donor islet supply as well as the risks associated with 
lifelong immunosuppression following this intervention. We and others are developing scalable bioprocesses to 
generate pancreatic cells from pluripotent stem cells, to purify the cells of interest, and to transplant them while 
circumventing the need for immunosuppression. This presentation will review upstream processing, downstream 
processing and formulation/delivery methods related to this challenging cell-based product. Examples of novel 
bioprocesses for pluripotent stem cell differentiation and pancreatic cell encapsulation in immunoprotective 
devices will be presented [2-4]. Avenues for future research and development include engineering devices that 
maximize cell oxygenation and survival while also allowing graft retrieval or replacement. One of these 
approaches is the engineering of vascularized tissue constructs using 3D printing [5]. As the cell therapy field 
continues to evolve and mature, complex combination products including therapeutic cells, biomaterials as well 
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